Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.54 |
| ▸ | CRHBP | P24387 | 2/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | CDC25C | P30307 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810294 | 0.85 | CRHBP (0.61) | TSHRKCNH2CRHBPCRHR2SIGMAR1 | |
| SCHEMBL23728043 | 0.84 | MEN1 (0.52) | TSHRKCNH2CRHBPCRHR2SIGMAR1 | |
| SCHEMBL3534499 | 0.83 | KCNH2 (0.53) | TSHRKCNH2SIGMAR1CDC25CMEN1 | |
| SCHEMBL6956249 | 0.82 | KCNH2 (0.60) | TSHRKCNH2SIGMAR1CDC25CMEN1 | |
| SCHEMBL777298 | 0.81 | KCNH2 (0.60) | TSHRKCNH2CRHBPCRHR2SIGMAR1 | |
| SCHEMBL9628028 | 0.81 | KCNH2 (0.74) | TSHRKCNH2CRHBPCRHR2SIGMAR1 | |
| SCHEMBL20380500 | 0.81 | CRHBP (0.59) | TSHRKCNH2CRHBPCRHR2CDC25C | |
| SCHEMBL3143117 | 0.80 | KCNH2 (0.64) | TSHRKCNH2CRHBPCRHR2SIGMAR1 | |
| SCHEMBL992030 | 0.80 | KCNH2 (0.50) | TSHRKCNH2SIGMAR1CDC25CMEN1 | |
| SCHEMBL15618795 | 0.80 | ALDH1A1 (0.51) | CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373694-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BioMarin Pharmaceutical Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065174-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7645752-B2 | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors | WYETH LLC (US) | 2010-01-12 | — | — | US | disclosed |
| WO-2008004117-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070203120-A1 | Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors | WYETH (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | HTR6, TPH1, HTR1A | TSHR 453/4885KCNH2 1505/4885CRHBP 712/4885 |
| US-20070203120-A1 | Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors | HTR5A, HTR2C, HTR2A | TSHR 193/4885KCNH2 559/4885CRHBP 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.